Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A.
Abstract
COVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second update. Given the rapidly changing evidence and general situation for COVID-19, the LSHBT established some recommendations and suggestions for the management of the patients with hematological malignancies taking into account the Lebanese condition, economic situation, and the facts that SARS-Cov-2 infection has apparently been devastating. In this article we present recommendations and proposals to reduce or to manage SARS-Cov-2 infection in the patients with myeloid and lymphoid hematological malignancies. © Copyright © 2021 Ibrahim, Noun, Khalil and Taher.
Description
Keywords
Hematological malignancies, Lshbt, Lymphoid, Myeloid, Sars-cov-2 infection, Acute lymphoblastic leukemia, Acute myeloid leukemia, Allogeneic hematopoietic stem cell transplantation, Article, Autologous stem cell transplantation, Burkitt lymphoma, Cancer chemotherapy, Cancer immunotherapy, Cancer recurrence, Chronic lymphatic leukemia, Chronic myeloid leukemia, Consolidation chemotherapy, Coronavirus disease 2019, Covid-19 testing, Cutaneous t cell lymphoma, Diffuse large b cell lymphoma, Health care system, Hematologic malignancy, Hematopoietic stem cell transplantation, Hodgkin disease, Human, Immunosuppressive treatment, Induction chemotherapy, Lymphoma, Maintenance therapy, Mantle cell lymphoma, Multiple myeloma, Myelodysplastic syndrome, Myeloproliferative neoplasm, Patient care, Peripheral blood stem cell transplantation, Peripheral t cell lymphoma, Polymerase chain reaction, Primary central nervous system lymphoma, Promyelocytic leukemia